Неинвазивные биомаркеры ранней диагностики болезни Альцгеймера в биологических жидкостях

Закрыть метаданные

Рекомендуем статьи по данной теме:

Глимфатическая дисфункция и нарушения сна: опосредованное влияние на болезнь Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;(4):7-12

Гинкголид B: механизмы нейробиологических эффектов, перспективы применения в терапии болезни Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;(4):22-27

Сравнительная оценка микробиоценоза слюны и ротоглотки у пациентов с мигренью. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;(4):55-62

Распространенность когнитивных расстройств у пациентов старшего возраста в Российской Федерации. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2024;(4-2):5-11

Когнитивные нарушения при сосудистых заболеваниях головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2024;(4-2):12-16

Сравнительная характеристика нейропсихологических и нейрометаболических показателей у пациентов с болезнью Альцгеймера и сосудистыми когнитивными расстройствами. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2024;(4-2):17-24

Нарушение внимания и управляющих функций при сосудистых когнитивных нарушениях и болезни Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2024;(4-2):25-32

Оценка значения расширенных периваскулярных пространств и ночной артериальной гипертензии в развитии болезни Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2024;(4-2):33-40

Когнитивные нарушения у пациентов с артериальной гипертензией. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2024;(4-2):41-48

Изменения электроэнцефалограммы у пациентов с болезнью Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2024;(4-2):72-76

Одной из актуальных проблем современного здравоохранения являются болезнь Альцгеймера (БА) и ее ранняя диагностика. Это обусловлено быстрым глобальным распространением БА, отсутствием патогенетической терапии и возможностью стабилизировать прогрессирование когнитивных нарушений на ранних стадиях заболевания. В современных условиях только аутопсия способна подтвердить диагноз БА с достоверностью в 100%, а классические лабораторно-инструментальные методы верификации диагноза сложно внедрить в рутинную клиническую практику, так как они имеют ряд ограничений. Именно поэтому исследование новых и доступных биомаркеров, выделенных из биологических жидкостей организма человека, представляет привлекательную перспективу для ранней диагностики БА. Обзор посвящен проблеме верификации БА с помощью маркеров в биологических жидкостях организма человека, которые возможно получить неинвазивным способом. Рассмотрены потенциальные биомаркеры БА в слюне, слезной жидкости, моче и назальном секрете, оценены их прогностические возможности в качестве индикаторов БА на ранней стадии.

Ключевые слова:

деменция

когнитивные нарушения

болезнь Альцгеймера

неинвазивные биомаркеры

слюна

слеза

моча

назальный секрет

Авторы:

Коваленко Е.А.

ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России (Пироговский университет);
ФГБУ «Федеральный центр мозга и нейротехнологий» Федерального медико-биологического агентства России

ORCID: 0000-0003-0828-9868

Махнович Е.В.

ORCID: 0000-0002-8606-5715

Первунина А.В.

ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России (Пироговский университет)

ORCID: 0000-0002-3233-1213

Гилёва Е.А.

ORCID: 0000-0002-6824-8868

Боголепова А.Н.

SPIN РИНЦ: 6775-0279
Scopus AuthorID: 6602240836
ORCID: 0000-0002-6327-3546

Дата поступления:

23.07.2024

Дата принятия в печать:

25.07.2024

Список литературы:

Hane FT, Robinson M, Lee BY, et al. Recent Progress in Alzheimer’s Disease Research, Part 3: Diagnosis and Treatment. J Alz Dis. 2017;57(3):645-665. https://doi.org/10.3233/JAD-160907
Bălașa AF, Chircov C, Grumezescu AM. Body Fluid Biomarkers for Alzheimer’s Disease-An Up-To-Date Overview. Biomedicines. 2020;15:8(10):421. https://doi.org/10.3390/biomedicines8100421
Dos Santos Picanco LC, Ozela PF, et al. Alzheimer’s Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment. Curr Med Chem. 2018;25:3141-3159. https://doi.org/10.2174/0929867323666161213101126
Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. The Lancet Neurology. 2021;20(6):484-496. https://doi.org/10.1016/S1474-4422(21)00066-1
Romaus-Sanjurjo D, Regueiro U, López-López M, et al. Alzheimer’s Disease Seen through the Eye: Ocular Alterations and Neurodegeneration. Int J Mol Sci. 2022;23(12):2486. https://doi.org/10.3390/ijms23052486
Ashton NJ, Ide M, Zetterberg H, Blennow K. Salivary Biomarkers for Alzheimer’s Disease and Related Disorders. Neurol Ther. 2019;8:83-94. https://doi.org/10.1007/s40120-019-00168-1
Bermejo-Pareja F, Antequera D, Vargas T, et al. Saliva levels of Abeta1-42 as potential biomarker of Alzheimer’s disease: a pilot study. BMC Neurology. 2010;10(7):108.
Lee M, Guo JP, Kennedy K, et al. A Method for Diagnosing Alzheimer’s Disease Based on Salivary Amyloid-β Protein 42 Levels. J Alz Dis. 2017;55(3):1175-1182. https://doi.org/10.3233/JAD-160748
Sabbagh MN, Shi J, Lee M, et al. Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer’s disease dementia from normal controls: preliminary findings. BMC Neurology. 2018;18(1):155. https://doi.org/10.1186/s12883-018-1160-y
Gleerup HS, Hasselbalch SG, Simonsen AH. Biomarkers for Alzheimer’s Disease in Saliva: A Systematic Review. Dis Mark. 2019;2019:4761054. https://doi.org/10.1155/2019/4761054
Nijakowski K, Owecki W, Jankowski J, Surdacka A. Salivary Biomarkers for Alzheimer’s Disease: A Systematic Review with Meta-Analysis. Int J Mol Sci. 2024;25(2):1168. https://doi.org/10.3390/ijms25021168
Zalewska A, Klimiuk A, Zięba S, et al. Salivary Gland Dysfunction and Salivary Redox Imbalance in Patients with Alzheimer’s Disease. Sci Rep. 2021;11:23904. https://doi.org/10.1038/s41598-021-03456-9
Sabaei M, Rahimian S, Haj ME, Ketabforoush A, et al. Salivary Levels of Disease-Related Biomarkers in the Early Stages of Parkinson’s and Alzheimer’s Disease: A Cross-Sectional Study. IBRO Neurosci Rep. 2023;14:285-292. https://doi.org/10.1016/j.ibneur.2023.03.004
Tvarijonaviciute A, Zamora C, Ceron JJ, et al. Salivary biomarkers in Alzheimer’s disease. Clin Oral Invest. 2020;24(10):3437-3444. https://doi.org/10.1007/s00784-020-03214-7
Cui Y, Zhang H, Zhu J, et al. Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer’s Disease Diagnosis. Brain Sci. 2022;12:595. https://doi.org/10.3390/brainsci12050595
Shi M, Sui YT, Peskind ER, et al. Salivary tau species are potential biomarkers of Alzheimer’s disease. J Alz Dis. 2011;27(2):299-305. https://doi.org/10.3233/JAD-2011-110731
Pekeles H, Qureshi HY, Paudel HK, et al. Development and validation of a salivary tau biomarker in Alzheimer’s disease. Alzheimers Dem. 2019;11:53-60. https://doi.org/10.1016/j.dadm.2018.03.003
Baker HM, Baker EN. Lactoferrin and iron: structural and dynamic aspects of binding and release. Biometals. 2004;17(3):209-216. https://doi.org/10.1023/b:biom.0000027694.40260.70
Arslan SY, Leung KP, Wu CD. The effect of lactoferrin on oral bacterial attachment. Oral Microbiol Immunol. 2009;24(5):411-416. https://doi.org/10.1111/j.1399-302X.2009.00537.x
González-Sánchez M, Bartolome F, Antequera D, et al. Decreased salivary lactoferrin levels are specific to Alzheimer’s disease. EBioMed. 2020;57:102834. https://doi.org/10.1016/j.ebiom.2020.102834
Reseco L, Atienza M, Fernandez-Alvarez M, et al. Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging. Alzheimer’s Res Ther. 2021;13(1):150. https://doi.org/10.1186/s13195-021-00891-8
Gleerup HS, Jensen CS, Høgh P, et al. Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer’s disease in a mixed memory clinic population. EBioMed. 2021;67:103361. https://doi.org/10.1016/j.ebiom.2021.103361
Thapa S, Lv M, Xu H. Acetylcholinesterase: A Primary Target for Drugs and Insecticides. Mini Rev Med Chem. 2017;17:1665-1676. https://doi.org/10.2174/1389557517666170120153930
Rotundo RL. Biogenesis, assembly and trafficking of acetylcholinesterase. J Neurochem. 2017;142 Suppl 2(Suppl 2):52-58. https://doi.org/10.1111/jnc.13982
Ahmadi-Motamayel F, Goodarzi MT, Tarazi S, Vahabian M. Evaluation of Salivary Acetylcholinesterase and Pseudocholinesterase in Patients with Alzheimer’s Disease: A Case-Control Study. Special Care Dent. 2019;39:39-44. https://doi.org/10.1111/scd.12342
Bakhtiari S, Moghadam NB, Ehsani M, et al. Can Salivary Acetylcholinesterase Be a Diagnostic Biomarker for Alzheimer? J Clin Diagn Res. 2017;11:ZC58-ZC60. https://doi.org/10.7860/JCDR/2017/21715.9192
Knezevic E, Nenic K, Milanovic V, Knezevic NN. The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders. Cells. 2023;12(23):2726.
De Souza-Talarico JN, Caramelli P, Nitrini R, Chaves EC. Effect of cortisol levels on working memory performance in elderly subjects with Alzheimer’s disease. Arq Neuropsiquiatr. 2008;66(3B):619-624. https://doi.org/10.1590/s0004-282x2008000500003
Peña-Bautista C, Baquero M, Ferrer I, et al. Neuropsychological assessment and cortisol levels in biofluids from early Alzheimer’s disease patients. Exp Gerontol. 2019;123:10-16.
Katsipis G, Tzekaki EE, Tsolaki M, Pantazaki AA. Salivary GFAP as a potential biomarker for diagnosis of mild cognitive impairment and Alzheimer’s disease and its correlation with neuroinflammation and apoptosis. J Neuroimmunol. 2021;361:577744. https://doi.org/10.1016/j.jneuroim.2021.577744
McNicholas K, François M, Liu JW, et al. Salivary inflammatory biomarkers are predictive of mild cognitive impairment and Alzheimer’s disease in a feasibility study. Front Aging Neurosci. 2022;14:1019296. https://doi.org/10.3389/fnagi.2022.1019296
Contini C, Serrao S, Manconi B, et al. Characterization of Cystatin B Interactome in Saliva from Healthy Elderly and Alzheimer’s Disease Patients. Life (Basel, Switzerland). 2023;13(3):748. https://doi.org/10.3390/life13030748
Peña-Bautista C, Torres-Cuevas I, Baquero M, et al. Early neurotransmission impairment in non-invasive Alzheimer Disease detection. Sci Rep. 2020;10(1):16396. https://doi.org/10.1038/s41598-020-73362-z
Marksteiner J, Defrancesco M, Humpel C. Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease. Front Aging Neurosci. 2022;14:1014305. https://doi.org/10.3389/fnagi.2022.1014305
Ryu IS, Kim DH, Ro JY, et al. The microRNA-485-3p Concentration in Salivary Exosome-Enriched Extracellular Vesicles Is Related to Amyloid β Deposition in the Brain of Patients with Alzheimer’s Disease. Clin Biochem. 2023;118:110603. https://doi.org/10.1016/j.clinbiochem.2023.110603
Pukhalskaia AE, Dyatlova AS, Linkova NS, et al. Sirtuins as Possible Predictors of Aging and Alzheimer’s Disease Development: Verification in the Hippocampus and Saliva. Bull Exp Biol Med. 2020;169(6):821-824. https://doi.org/10.1007/s10517-020-04986-4
Khalifeh M, Read MI, Barreto GE, Sahebkar A. Trehalose against Alzheimer’s Disease: Insights into a Potential Therapy. BioEssays. 2020;42:e1900195. https://doi.org/10.1002/bies.201900195
Lau HC, Lee IK, Ko PW, et al. Non-Invasive Screening for Alzheimer’s Disease by Sensing Salivary Sugar Using Drosophila Cells Expressing Gustatory Receptor (Gr5a) Immobilized on an Extended Gate Ion-Sensitive Field-Effect Transistor (EG-ISFET) Biosensor. PLoS One. 2015;10:e0117810. https://doi.org/10.1371/journal.pone.0117810
Haigh BJ, Stewart KW, Whelan JR, et al. Alterations in the salivary proteome associated with periodontitis. J Clin Periodontol. 2010;37(3):241-247. https://doi.org/10.1111/j.1600-051X.2009.01525.x
Al-Amrani S, Al-Jabri Z, Al-Zaabi A, et al. Proteomics: Concepts and Applications in Human Medicine. World J Biol Chem. 2021;12:57-69. https://doi.org/10.4331/wjbc.v12.i5.57
Huan T, Tran T, Zheng J, et al. Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer’s Disease. J Alz Dis. 2018;65:1401-1416. https://doi.org/10.3233/JAD-180711
François M, Karpe A, Liu JW, et al. Salivaomics as a Potential Tool for Predicting Alzheimer’s Disease During the Early Stages of Neurodegeneration. J Alz Dis. 2021;82(3):1301-1313. https://doi.org/10.3233/JAD-210283
Liang Q, Liu H, Li X, Zhang Y. High performance liquid chromatography coupled with high resolution mass spectrometry-based characterization of lipidomic responses from rats with kidney injuries. RSC Adv. 2021;36:20250-20258. https://doi.org/10.1039/c8ra02805b
Marksteiner J, Oberacher H, Humpel C. Acyl-Alkyl-Phosphatidlycholines are Decreased in Saliva of Patients with Alzheimer’s Disease as Identified by Targeted Metabolomics. J Alzheimers Dis. 2019;68(2):583-589. https://doi.org/10.3233/JAD-181278
Eldem E, Barve A, Sallin O, et al. Salivary Proteomics Identifies Transthyretin as a Biomarker of Early Dementia Conversion. J Alz Dis Rep. 2022;6:31-41. https://doi.org/10.3233/ADR-210056
Wan J, Fan H. Oral Microbiome and Alzheimer’s Disease. Microorganisms. 2023;11:2550. https://doi.org/10.3390/microorganisms11102550
Zürcher C, Humpel C. Saliva: a challenging human fluid to diagnose brain disorders with a focus on Alzheimer’s disease. Neural Regeneration Res. 2023;18(12):2606-2610. https://doi.org/10.4103/1673-5374.373675
Hu X, McKenzie CA, Smith C, et al. The remarkable complexity of the brain microbiome in health and disease. BioRxiv. 2023;2(6):527297. https://doi.org/10.1101/2023.02.06.527297
Kaštelan S, Braš M, Pjevač N, et al. Tear Biomarkers and Alzheimer’s Disease. International Journal of Mol Sci. 2023;24(17):13429. https://doi.org/10.3390/ijms241713429
Zhou L, Zhao SZ, Koh SK, et al. In-depth analysis of the human tear proteome. J Proteom. 2012;75(13):3877-3885. https://doi.org/10.1016/j.jprot.2012.04.053
Del Prete S, Marasco D, Sabetta R, et al. Tear Liquid for Predictive Diagnosis of Alzheimer’s Disease. Sci Rep. 2021;4(3):26. https://doi.org/10.3390/reports4030026
Wang YR, Chuang HC, Tripathi A, et al. High-Sensitivity and Trace-Amount Specimen Electrochemical Sensors for Exploring the Levels of β-Amyloid in Human Blood and Tears. Analyt Chem. 2021;93(22):8099-8106. https://doi.org/10.1021/acs.analchem.0c04980
Gijs M, Ramakers IHGB, Visser PJ, et al. Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. Sci Rep. 2021;11(1):22675.
Gharbiya M, Visioli G, Trebbastoni A, et al. Beta-Amyloid Peptide in Tears: An Early Diagnostic Marker of Alzheimer’s Disease Correlated with Choroidal Thickness. Int J Mol Sci. 2023;24(3):2590. https://doi.org/10.3390/ijms24032590
Kalló G, Emri M, Varga Z, et al. Changes in the Chemical Barrier Composition of Tears in Alzheimer’s Disease Reveal Potential Tear Diagnostic Biomarkers. PloS One. 2016;11(6):e0158000. https://doi.org/10.1371/journal.pone.0158000
Kenny A, Jiménez-Mateos EM, Zea-Sevilla MA, et al. Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer’s disease. Sci Rep. 2019;9(1):15437. https://doi.org/10.1038/s41598-019-51837-y
van de Sande N, Ramakers IHGB, Visser PJ, et al. Tear biomarkers for Alzheimer’s disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study. BMC Neurology. 2023;23(1):293. https://doi.org/10.1186/s12883-023-03335-y
Lim JK, Li QX, He Z, et al. The Eye as a Biomarker for Alzheimer’s Disease. Front Neurosci. 2016;10:536. https://doi.org/10.3389/fnins.2016.00536
Karki HP, Jang Y, Jung J, Oh J. Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of Alzheimer’s disease. J Nanobiotechnol. 2021;19(1):72. https://doi.org/10.1186/s12951-021-00814-7
Kurbatova N, Garg M, Whiley L, et al. Urinary metabolic phenotyping for Alzheimer’s disease. Sci Rep. 2020;10(1):21745. https://doi.org/10.1038/s41598-020-78031-9
Watanabe Y, Hirao Y, Kasuga K, et al. Urinary Apolipoprotein C3 Is a Potential Biomarker for Alzheimer’s Disease. Dementia Geriatr Cogn Disord. 2020;10(3):94-104. https://doi.org/10.1159/000509561
Monte SM, Ghanbari K, Frey WH, et al. Characterization of the AD7C-NTP cDNA expression in Alzheimer’s disease and measurement of a 41-kD protein in cerebrospinal fluid. J Clin Invest. 1997;100:3093-3104. https://doi.org/10.1172/JCI119864
Li Y, Kang M, Sheng C, et al. Relationship between Urinary Alzheimer-Associated Neuronal Thread Protein and Apolipoprotein Epsilon 4 Allele in the Cognitively Normal Population. Neural Plasticity. 2020;2020:9742138. https://doi.org/10.1155/2020/9742138
Lv S, Zhou X, Li Y, et al. The Association Between Plasma α-Synuclein (α-syn) Protein, Urinary Alzheimer-Associated Neuronal Thread Protein (AD7c-NTP), and Apolipoprotein Epsilon 4 (ApoE 4) Alleles and Cognitive Decline in 60 Patients with Alzheimer’s Disease Compared with 28 Age-Matched Normal Individuals. Med Sci Mon. 2021;27:e932998. https://doi.org/10.12659/MSM.932998
Wang Y, Pan F, Xie F, et al. Correlation Between Urine Formaldehyde and Cognitive Abilities in the Clinical Spectrum of Alzheimer’s Disease. Front Aging Neurosci. 2022;14:820385. https://doi.org/10.3389/fnagi.2022.820385
Martinelli F, Heinken A, Henning AK, et al. Whole-body modelling reveals microbiome and genomic interactions on reduced urine formate levels in Alzheimer’s disease. Res Square. 2023;rs.3.rs-3306891. https://doi.org/10.21203/rs.3.rs-3306891/v1
García-Blanco A, Peña-Bautista C, Oger C, et al. Reliable determination of new lipid peroxidation compounds as potential early Alzheimer Disease biomarkers. Talanta. 2018;184:193-201. https://doi.org/10.1016/j.talanta.2018.03.002
Praticò D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch Neurol. 2002;59(6):972-976. https://doi.org/10.1001/archneur.59.6.972
Lee SH, Kim I, Chung BC. Increased urinary level of oxidized nucleosides in patients with mild-to-moderate Alzheimer’s disease. Clin Biochem. 2007;40(13-14):936-938. https://doi.org/10.1016/j.clinbiochem.2006.11.021
Arnold SE, Lee EB, Moberg PJ, et al. Olfactory epithelium amyloid‐β and paired helical filament‐tau pathology in Alzheimer disease. Ann neurol. 2010;67(4):462-469. https://doi.org/10.1002/ana.21910
Ayala-Grosso CA, Pieruzzini R, Diaz-Solano D, et al. Amyloid-aβ Peptide in olfactory mucosa and mesenchymal stromal cells of mild cognitive impairment and Alzheimer’s disease patients. Brain Pathology. 2015;25(2):136-145. https://doi.org/10.1111/bpa.12169
Liu Z, Kameshima N, Nanjo T, et al. Development of a High-Sensitivity Method for the Measurement of Human Nasal Aβ42, Tau, and Phosphorylated Tau. J Alzheimer’s Dis. 2018;62(2):737-744. https://doi.org/10.3233/JAD-170962
Yoo SJ, Lee JH, Kim SY, et al. Differential spatial expression of peripheral olfactory neuron-derived BACE1 induces olfactory impairment by region-specific accumulation of β-amyloid oligomer. Cell Death Dis. 2017;8(8):e2977. https://doi.org/10.1038/cddis.2017.349
Hock C, Golombowski S, Müller-Spahn F, et al. Histological markers in nasal mucosa of patients with Alzheimer’s disease. Eur Neurol. 1998;40(1):31-36. https://doi.org/10.1159/000007953
Attems J, Walker L, Jellinger KA. Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol. 2014;127(4):459-475. https://doi.org/10.1007/s00401-014-1261-7
Passali GC, Politi L, Crisanti A, et al. Tau protein detection in anosmic Alzheimer’s disease patient’s nasal secretions. Chemosensory Perception. 2015;8(4):201-206. https://doi.org/10.1007/s12078-015-9198-3
Moon J, Lee ST, Kong IG, et al. Early diagnosis of Alzheimer’s disease from elevated olfactory mucosal miR-206 level. Sci Rep. 2016;6:20364. https://doi.org/10.1038/srep20364

Закрыть метаданные